CBD may boost memory and ease Alzheimer's symptoms

A recent study by the University of Augusta, published in the journal eNeuro, suggests that cannabidiol (CBD) may help reduce brain inflammation and improve cognitive function in Alzheimer’s disease.

Conducted on mice genetically predisposed to develop symptoms similar to those of Alzheimer's disease, this study showed that daily inhalation of CBD reduced markers of inflammation and led to measurable improvements in memory-related behavior.

Although these results are still at the preclinical stage, they add to a growing body of evidence that positions the CBD as a potential modulator of the immune system rather than merely as a way to relieve symptoms.

According to the principal investigator Babak Baban, professor and associate dean for research at the Medical College of Georgia, the team approached the disease from a new angle, viewing it as a autoinflammatory condition, in which the brain's immune system becomes overactive and self-perpetuates.

«Alzheimer’s disease remains one of the most pressing challenges in medicine, affecting millions of families around the world, but there is still no truly effective treatment,» explained Mr. Baban. «CBD, known for its powerful anti-inflammatory and immunomodulatory properties, offered a new tool for testing this hypothesis.»

Beyond amyloid plaques and tau tangles

For decades, research on Alzheimer's disease has focused on the accumulation of amyloid plaques and’tau tangles, two protein abnormalities found in patients’ brains. But despite the billions invested in targeting these characteristics, clinical results have remained disappointing. Scientists are increasingly focusing on the role of the’chronic inflammation and immune dysfunction in the progression of the disease.

The team at Augusta University focused on two key immune pathways: the’indoleamine 2,3-dioxygenase (IDO) and the cyclic GMP-AMP synthase (cGAS). Both play an important role in regulating the brain's immune response and have been linked to neurodegenerative and inflammatory disorders.

In their study, the researchers exposed mice predisposed to Alzheimer's disease to daily doses of Inhaled CBD for four weeks. This method of administration was chosen because it allows for rapid absorption and regular dosing compared to oral administration.

Brain tissue samples and behavioral tests revealed that mice treated with CBD showed a significant reduction in IDO and cGAS activity, suggesting that the compound may influence the functioning of the immune system in the brain.

Restoring Balance to the Brain's Immune System

The effects of CBD extend beyond molecular markers. The treated mice showed behavioral improvements consistent with reduced anxiety and improved memory performance. During the open-field test, they spent more time exploring the central areas, suggesting a decrease in anxiety. During the New Object Recognition Test, they showed a greater interest in the new objects, a sign of improved memory.

A more in-depth analysis revealed that CBD treatment reduced levels of inflammatory molecules such as’interferon gamma, theinterleukin-1 beta and the tumor necrosis factor alpha, while increasing levels of’interleukin-10, an anti-inflammatory cytokine. This shift from a pro-inflammatory immune environment to a more balanced one corresponds to the CBD's well-documented anti-inflammatory potential.

Flow cytometry, a technique used to analyze immune cell populations, confirmed that the Mice treated with CBD had fewer infiltrating macrophages, immune cells that generally contribute to increased inflammation in brains affected by Alzheimer's disease. These findings suggest that CBD does more than just relieve symptoms; it appears to recalibrate the brain's immune environment.

«The degree of interaction between the two immune pathways was greater than expected,» noted Mr. Baban. «Even more surprising was how effectively CBD could regulate both at the same time, revealing a unified mechanism of immune control in the brain.»

The concept of Alzheimer's disease as autoinflammatory disease is relatively new, having gained popularity only in recent years. This study is one of the first to establish a link between the systems IDO and cGAS-STING as the main drivers of neuroinflammation, and to show that the Inhaled CBD can regulate both at the same time.

«CBD is not a «cure» for Alzheimer’s disease, and our findings should not be interpreted that way,» Baban emphasized. «What we have demonstrated is a mechanistic basis: CBD acts as a precision immune modulator. It does not shut down the immune system; it restores balance.»

From Animal Models to Human Trials

Although the results are promising, the researchers point out that these findings are based on animal models and that human biology may respond differently. Only a single dosage and duration were tested, leaving questions about optimal treatment protocols unanswered. The study has also focused on specific immune pathways, which means that other important mechanisms may still be discovered.

Despite these reservations, the team at Augusta University remains optimistic. They have already filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) to begin testing inhaled CBD in people with Alzheimer’s disease and other brain disorders. such as glioblastoma. She also plans to expand her research to related conditions such as vascular dementia and autoimmune diseases, which have similar inflammatory profiles.

«Our next goal is to translate these findings into clinical applications,» said Mr. Baban. «Ultimately, we hope to redefine neurodegeneration as a disease linked to an immune imbalance and develop therapies that restore the brain’s homeostasis, rather than merely suppressing its symptoms.»